A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission

OBJECTIVES: Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatzidionysiou, Katerina, Turesson, Carl, Teleman, Annika, Knight, Ann, Lindqvist, Elisabet, Larsson, Per, Cöster, Lars, Forslind, Kristina, van Vollenhoven, Ronald, Heimbürger, Mikael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716561/
https://www.ncbi.nlm.nih.gov/pubmed/26819752
http://dx.doi.org/10.1136/rmdopen-2015-000133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716561/
https://www.ncbi.nlm.nih.gov/pubmed/26819752
http://dx.doi.org/10.1136/rmdopen-2015-000133

Ejemplares similares